Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel (Q34005908)

30 July 2017

1 reference

title

Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel (English)

1 reference

30 July 2017

0 references

1 reference

Thomas E Stinchcombe

1

1 reference

30 July 2017

publication date

1 August 2007

1 reference

30 July 2017

1 reference

30 July 2017

volume

2

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

415-423

1 reference

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Taxol: a novel investigational antimicrotubule agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Promotion of microtubule assembly in vitro by taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

21 January 2018

The taxanes: an update

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Hypersensitivity reactions from taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Novel formulations of taxanes: a review. Old wine in a new bottle?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Novel markers for poor prognosis in head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-in-human safety and dose-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

Caveolae-deficient Endothelial Cells Show Defects in the Uptake and Transport of Albuminin Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17435889.2.4.415

21 January 2018

Identifiers

DOI

10.2217/17435889.2.4.415

1 reference

release_tjaojawbavc4poheezns7jnrg4

30 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tjaojawbavc4poheezns7jnrg4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference